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Abstract
Background: Chimeric read-through RNAs are transcripts originating from two directly adjacent genes (<10 kb) on
the same DNA strand. Although they are found in next-generation whole transcriptome sequencing (RNA-Seq) data
on a regular basis, investigating them further has usually been refrained from. Therefore, their expression patterns
or functions in general, and in oncogenesis in particular, are poorly understood.
Results: We used paired-end RNA-Seq and a specifically designed computational data analysis pipeline (FusionSeq)
to nominate read-through events in a small discovery set of renal cell carcinomas (RCC) and confirmed them in a
larger validation cohort.
324 read-through events were called overall; 22/27 (81%) selected nominees passed validation with conventional
PCR and were sequenced at the junction region. We frequently identified various isoforms of a given read-through
event. 2/22 read-throughs were up-regulated: BC039389-GATM was higher expressed in RCC compared to benign
adjacent kidney; KLK4-KRSP1 was expressed in 46/169 (27%) RCCs, but rarely in normal tissue. KLK4-KRSP1 expression
was associated with worse clinical outcome in the patient cohort. In cell lines, both read-throughs influenced
molecular mechanisms (i.e. target gene expression or migration/invasion) in a way that counteracted the effect of
the respective parent transcript GATM or KLK4.
Conclusions: Our data suggests that the up-regulation of read-through RNA chimeras in tumors is not random but
causes regulatory effects on cellular mechanisms and may impact patient survival.
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Background
With the launching of large consortium projects like EN-
CODE or FANTOM, the research community has become
highly aware of an underestimated complexity of the
eukaryotic genome and transcriptome. The “one gene - one
RNA - one protein” paradigm has been abandoned by real-
izing that coding and non-coding RNA is exerting multiple
functions in regulating cellular systems [1]. New technolo-
gies were utilized on sequencing the transcriptome to iden-
tify new classes of RNAs, for example chimeric RNA
molecules containing exons from two directly adjacent
genes of the same transcriptional orientation, termed read-
through RNAs. They supposedly arise through mechanisms
not a priori requiring genomic rearrangements [2-4]. In
fact, read-throughs favorably occur at minimal intergenic
distance between the parent genes (approx. 10 kb) [5].
Several years ago came the first reports of systematic large-
scale computational analyses of read-through RNAs
which were termed “Transcription-mediated gene fu-
sion”, “Tandem chimerism” and “Conjoined genes”
[5-7]. The authors of these studies used deposited data
from EST data bases and confirmed their predictions
only in normal human tissues and a few cell lines. One
can find only two recent comprehensive read-through
studies in tumors, one on breast cancer [8] and one on
prostate cancer [9]. Two additional studies in cancer re-
port on fusion transcripts/chimeric RNAs of which the
vast majority is suspected of being read-throughs, al-
though this is not clearly documented [10,11]. In other
RNA-Seq papers, read-throughs are mentioned as a side
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note or in the supplement as they were not the focus of
interest [2,12,13]. The only comprehensive study on renal
cancer employing RNA-Seq has explicitly excluded read-
throughs from the list of RNA fusions [14]. RNA read-
through formation seems to be evolutionary conserved. A
study in Arabidopsis thaliana demonstrated evidence, that
depletion of RNA binding proteins causes impairement of
transcription termination, thereby enhancing the expres-
sion of RNA read-throughs which in parallel influence the
expression levels of their parent genes [15]. Little is
known about the biological or disease-associated function
of read-through RNAs in humans. Some read-throughs
might encode functional chimeric proteins as exemplified
in the case of TWE-PRIL [16] or LY75-CD302 [17].
SLC45A3-ELK4 as the prototype read-through in prostate
cancer is not just a biomarker [2,3] but has been shown
to induce prostate cancer proliferation in-vitro in a recent
study by Zhang et al. [4]. The same group also demon-
strated that SLC45A3-ELK4 is generated by cis-splicing
and that its formation is mechanistically intertwined with
androgen signaling. In summary, chimeric read-through
transcripts may have implications in carcinogenesis.
Here, we explore RNA read-throughs by sequencing
the transcriptome of human renal cell carcinoma (RCC),
a malignancy where nothing major is known on read-
through expression yet, and elaborate on the potential func-
tions of two examples relevant to renal carcinogenesis.
Results
Numerous read-through RNA chimeras are expressed
in RCC
The RNA-Seq analysis by FusionSeq called 324 read-
throughs across the sample set representing about half
(mean of 52.3%) of all RNA chimera calls (Figure 1A &
Additional file 1: Figure S1). Most of them had low (≤2)
RESPER (Ratio of empirically computed supportive paired-
end reads) values which is interpretable as humble expres-
sion levels of most read-throughs. RESPER not only is a
confidence score for the candidate call by the software, it
also gives an estimate about the expression level of the
chimeric transcript. Due to limited availability of RCC
tissue we selected an arbitrary number of top- (RESPER > 2
(n = 13)) and bottom- (RESPER < 0.4 (n = 14)) candidates
and confirmed 11 of 13 (85%) top- and 11 of 14 (79%)
bottom-candidates with conventional reverse transcription
(RT)-PCR (Figure 1B & Additional file 1: Figure S2). Based
on this finding, we assume that candidates with RESPER
between 0.4 and 2 also have a true positive rate around 79-
Figure 1 A panel of read-throughs is expressed in RCC. (A) The fraction of different classes of RNA chimeras called by FusionSeq from the RNASeq data in
seven frozen RCC samples. The clinical characteristics of the samples are given elsewhere [30]. ccRCC, clear cell RCC; chrRCC, chromophobe RCC; tRCC, Xp11
translocation RCC. (B) 27 read-throughs which were chosen for further validation by reverse transcription (RT)-PCR. Plotted are the individual RESPER scores
per sample and the mean RESPER with range if the read-through was found in more than 1 sample. (C) Quantitative evaluation of 12 read-throughs by
TaqMan assays in frozen tissue of RCC and matched adjacent normal kidney, plotted as Tukey boxplots. No read-through has significant differential expression
between tumor and normal tissue as calculated by student’s t-test with correction for multiple testing by Bonferroni method. The blue outlier dot in
TMED6-COG8 is the tRCC whose detailed analysis is featured elsewhere [30].
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85%. Sanger Sequencing of the PCR products enabled us to
determine the read-throughs’ junction sequence and exon
composition around this region (Table 1). Most read-
through events (13 of 22) generated two to five different
isoforms. For nine read-throughs existed only a single tran-
script. The most obvious splicing pattern (53% of isoforms)
is the exclusion of terminal exons from the upstream parent
gene and initial exons from the downstream parent gene,
using known exon-intron boundaries. Other isoforms (39%)
used new GT—AG splice sites in introns or exons to
lengthen or shorten an exon or to introduce a new exon
from intergenic sequence. A third group of isoforms (10%)
retained intergenic sequence, in some instances suggesting
that the 3′ parent contributes an extended 3′UTR to the 5′
parent gene. Knowing the read-throughs’ exon compositions
enabled us to build putative coding sequences. Only in 12%
of the isoforms the exon junction was in-frame which might
fuse both parent open reading frames (ORFs) forming an in-
tact fusion ORF (Table 2). Most often, exon junctions were
outside of the 5′ parent’s ORF (31%) or caused frameshifts
and premature stop codons in the 5′ genes (35%). About
20% of the isoforms were originating from read-throughs
between known genes and non-coding RNAs, merely anno-
tated with data bank accession numbers, and therefore
termed “non-classical”. The functional consequence in such
instances is unclear. One read-through was a known anti-
sense transcript [11].
In this data set, Fusion Seq called many read-throughs
only in one or two samples (Figure 1B). However, their ex-
pression was mostly not restricted to just one sample as
shown in subsequent quantitative measurement of read-
through expression in a larger sample set. We selected 14
read-throughs (Mean RESPER > 1 in Figure 1B and/or en-
coding putative fusion protein) for differential expression
analysis by TaqMan qPCR and found that 12 were
expressed in all RCC samples (this cohort comprising one
Xp11 translocation RCC (tRCC), one chromophobe RCC
(chrRCC), four papillary RCCs (pRCC), 26 clear cell RCCs
(ccRCC)) and at levels that were equal to their matched
benign kidney tissues (Figure 1C). However, two read-
throughs presented with exceptional expression pattern.
Read-throughs BC039389-GATM and KLK4-KRSP1 are
overexpressed in RCC
The first read-through which caught our interest was
BC039389-GATM (BG) occurring between the non-cod-
ing RNA BC039389 with unknown function and GATM
(Glycine amidinotransferase; alias AGAT) (Figure 2A).
Alternative splicing of GATM exons 2 or 3 produces the
two BC039389-GATM isoforms v1 and v2. BGv1 was
expressed in all RCC samples and the levels were signifi-
cantly elevated compared to the matched normal kidney
tissues (Figure 2B). A direct comparison in 14 samples
revealed that the levels of the minor BC039389-GATM
variant (BGv2) were one log lower in most cancer tis-
sues and not detectable in most normal tissues
(Figure 2C).
The second interesting read-through was KLK4-KRSP1
(KK) involving KLK4, a member of the serine protease
family of tissue kallikreins and its pseudogene KRSP1
(Figure 3A). After the initial confirmation of KK in the
index case (chrRCC), we screened a larger cohort and found
KLK4-KRSP1 isoform 1 (KKv1) expression restricted to 46
of 169 (27%) RCCs (Figure 3B). We also checked KKv1 ex-
pression in matching normal kidney of the 46 cases and
found that only ten had detectable levels of KKv1. Further-
more, our screen revealed that expression of the minor vari-
ant KKv2 was restricted to only RCCs with highest KKv1
expression (18 of 169 (11%)) (Figure 3C). Since KKv3 was
even weaker expressed than KKv2 (see Additional file 1: Fig-
ure S2) and KKv4 and KKv5 were detected later as bypro-
ducts in a cloning effort to generate KK ORFs, the focus
was set on screening expression of KKv1 and KKv2 only.
We designed several TaqMan assays targeting the read-
throughs’ parent genes to measure the expression profile of
exons excluded (wild-type) or included (total) in the read-
through transcripts (see Figures 2A and 3A for the location
of the different assays). Tumors expressing BGv1 had signifi-
cantly elevated total (tot) and wild-type (wt) levels of the 5′
parent BC039389 compared to matched normal kindey
(Figure 4A). Despite elevated BGv1, total levels of the 3′ par-
ent GATM were significantly reduced. GATM wild-type
transcript was not differentially expressed. Similarly, tumors
expressing KKv1 also had significantly elevated total and
wild-type levels of the 5′ parent KLK4, when compared to
their matched normal tissues (Figure 4B, left panel). Similar
to the reduction of GATMtot in BGv1-expressing samples,
there was a trend of reduction seen for KRSP1tot in KKv1-
expressing samples, too, although not significant. KRSP1wt
remained unchanged. For the purpose of comparison, the
measurements in tumors without any KKv1 expression dif-
fered considerably (Figure 4B, right panel). There, KLK4tot
and KLK4wt levels were significantly reduced when com-
pared to their matched normal tissue. Taken together, this
suggests that high expression of the 5′ parent might sway
read-through expression and that a reduction of the 3′ par-
ent may also contribute to read-through expression.
Having identified BG and KK as potential novel players in
human RCC, we went on screening a panel of 47 cell lines.
All cell lines expressed BGv1 (Additional file 1: Figure S3A),
24 cell lines expressed BGv2 (Additional file 1: Figure S3B)
and KKv1 expression was restricted to 13 cell lines (Add-
itional file 1: Figure S3C).
Clinical parameters of RCCs expressing KLK4-KRSP1
We performed some association analyses of KKv1 expres-
sion with known clinical parameters. KKv1 expression cor-
related significantly with larger tumors, high grade tumors
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Table 1 Characteristics of 22 confirmed read-throughs in RCC
Read-through Type Transcript
isoforms
Exon junction Exclusion terminal/
initial exons
Modification/
Introduction exon
Retention intergenic
sequence
GT-AG
splice site
Supporting
EST
Coding
consequence
TaqMan
MIA2-CTAGE5 classical 1 M6middle-C4 x y N 1 x
WRB-SH3BGR classical 2 W4-S3 x y Y 1 x
W4-S3 (S6-7 out) x y 1 x
FAM175A-HELQ classical 1 F8-H3 x y Y 1 x
TCEA NC-RAB9A classical 2 T4-R2 x y N 2 x
T4-R2 x y 2 x
FXYD2-DSCAML1 classical 5 F3e-D2 x y N 2 x
(F3c out) F3e-D2 x y N 2 x
F3e-D2 (D2 intra-spliced) x y N 2 x
(F3c out) F3e-D2 (D2 intra-
spliced)
x y N 2 x
F3e-intergenic seq-D2 x n N 2 x
SLC12A4-LCAT classical 1 S26middle-L2 x y N 2
CD81-TSSC4 classical 1 C8middle-T1 x y N 2
VAMP8-VAMP5 classical 3 V3middle-V2 x n Y 2 x
(V3 intra-spliced) V3middle-V2 x n Y 1 x
V3middle2-V2 x n Y 2 x
STX16-NPEPL1 classical 4 S8-N2a (N3 out) x y Y 1 x
S8-intergenic ex on 2-N2a (N3
out)
x y Y 3; fsX42
S8-intergenic ex ons 1,2-N2b
(N3 out)
x y Y 3; fsX92
S8-N2b (N3 out) x y Y 3; fsX42
TMED6-COG8 * classical 3 T1-C2 x y Y 3; fsX17 x
T2-C2 x y Y 3; fsX4 x
T3-C2 x y Y 3; fsX17
TMEM27-ACE2 classical 4 T5-A2 x y N 3; fsX9
T5-A2middle x y N 3; fsX16
T4-A2 x y N 3; fsX9
T4-A2middle x y N 3; fsX16
METTL21B-TSFM classical 1 M2-T2 (T5 out) x y Y 3; fsX105
GLYCTK-DNAH1 classical 3 (G2 out) G3-D1middle x y N 3; fsX14
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Table 1 Characteristics of 22 confirmed read-throughs in RCC (Continued)
G3-intergenic seq-D1middle
(D1c in)
x x y N 3; fsX1
G3-D1middle x y N 3; fsX14
AKO97351-SLC6A
16
classical 5 A1-S2 x y N 3; fsX23
A2-S2 x y N 3; fsX22
A3middle-S2 x y N 2
A1-S8 x y N 3; fsX7
A1-S9 x y N 3; fsX2
KLK4-KRSP1 not classical 5 KKv1 K3-K4 x y Y 4; fsX56 x
KKv2 K5middle-K4 x n Y 4; fsX3 x
KKv3 K5middle2-K4 x y Y 4; fsX56
KKv4 K1-K4 x y Y 4; fsX56
KKv5 K1-K3 x y Y 4; fsX72
BC039389-GA TM not classical 2 BGv1 B3-G2 x n Y 4 x
BGv2 B3-G3 x y Y 4 x
AK311380-
MVB12A
not classical 2 A2-M2 x y Y 4
(A1 intra-spliced) A2-M2 x y Y 4
BC041984-
TMEM135
not classical 1 B2-T2 x y N 4
RNPEP-ELF3 not classical 1 Ri6middlie-E1middle x y Y 5 x
ACSM2A-
AX747287
extended 3′
UTR
2 A 15-intergenic seq-A x N 2 x
A 15middle-Amiddle x n N 2
TAGLN-
AK126420
extended 3′
UTR
1 T5-intergenic seq-A x Y 2 x
STXBP5-
BC043173
extended 3′
UTR
1 S 28-intergenic seq-B x y 2 x
TOTAL: 22 51 27 (53%) 20 (39%) 5 (10%)
Read-throughs are sorted in three types: classical, if the parent genes’ structure and ORF are well defined; non-classical, if at least one parent gene is incompletely defined non-coding RNA or pseudogene or the read-
through being an antisense transcript; extended 3′UTR, if the 3′ parent likely represents a longer 3′UTR sequence to complement the 5′ parent with. The number of isoforms per read-through is given in the third
column, together with the names of KLK4-KRSP1 and BC039389-GATM isoforms specifically featured in this publication (labeled red). The exon junction is given between 5′ parent and 3′ parent gene according to their
NCBI entries and hg19 assembly, as exemplified with WRB-SH3BGR: WRB exon 4 (W4) is spliced to SH3BGR exon 3 (S3). A second isoform with same exon junction exists where SH3BGR exons 6 and 7 are spliced out
(S6-7 out). Some exons were shortened at previously unknown positions (termed middle, or middle2 if different positions were used) before they were connected to the other parent gene. Some exons were spliced to
lose a short part of the sequence inside the exon (intra-spliced). Some isoforms retained the entire or partial intergenic sequence (seq) between the parent genes or spliced elements of it (exons). An exon junction
with intronic sequence is indicated as “i” (for example, Ri6middle = shortened intron 6 of RNPEP)). The second to last column shows the coding consequence of the exon junction further described in Table 2. The last
column “TaqMan” indicates the isoforms that were targeted in the expression screening depicted in Figure 1C. *TMED6-COG8 has been identified as part of this study but evaluated in detail elsewhere [30].
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and the histological subtype (Table 3). Notably, all chro-
mophobe (chrRCC) and 50% papillary type 2 (pRCC type
2), compared to 20% clear cell (ccRCC) and 13% papillary
type 1 RCCs in our cohort expressed KKv1. Survival ana-
lysis of the ccRCC sub-cohort (n = 119) showed a signifi-
cantly reduced overall survival for patients with KKv1 was
expressing tumors (Figure 5).
BC039389-GATM and KLK4-KRSP1 influence gene
regulation in a converse manner compared to their
respective parent transcript
Having identified several cell lines expressing BG and KK,
we were able to perform some functional analyses. We first
searched for target genes by knocking-down the major iso-
forms of BG read-through (BGv1) and KK read-through
(KKv1) in selected cell lines (Additional file 1: Figures S4A
and S5A). Subsequent genome-wide microarray analyses
revealed several significantly differentially regulated genes
(Figure 6A,B & Additional file 1: Figures S4B-C and S5B-C)
of which 13 with tumor-related functions (i.e. apoptosis,
mTOR signaling, cell cycle regulation, directional cell
movement) were selected for re-evaluation on RNA and
protein level (Figure 6C-F & Additional file 1: Figures S4D-
E & S5D). Most striking was the distinctively pronounced
reciprocal regulation of Interleukin 8 (IL8) in BG knock-
down (siBG) versus the knock-down of the functional par-
ent gene GATM (siGATMwt). siBG induced IL8 whereas
siGATMwt reduced it (Figure 6C). IL8 protein levels were
too low to be detected by Western Blot. Therefore, we used
ELISA to show that the IL8 regulation was also apparent
on protein level in the cell lines (Figure 6D). In concord-
ance with the cell line data, we saw a trend of increased IL8
levels in normal tissues (approximating the BG knock-
down situation) and reduced IL8 in tumor tissues (Add-
itional file 1: Figure S6A).
A similar reciprocal regulation was observed for Lipo-
polysaccharide-induced TNF factor (LITAF) in KKv1
knock-down (siKKv1) versus the knock-down of the
functional parent gene KLK4 (siKLK4wt). siKKv1 re-
duced LITAF whereas siKLK4wt induced its expression
(Figure 6E). LITAF protein was clearly detectable by
Western Blot; but although there was a downregulation
of LITAF upon KKv1 knock-down, an upregulation of
LITAF upon siKLK4wt was visible only weakly in Caki-2
and A704 (Figure 6 F). We concluded that Western Blot
may not be sufficiently sensitive to detect the small in-
crease in LITAF in all cell lines reliably. To substantiate
the cell line data, quantitative measurements in tumor
tissues were conducted and confirmed significantly re-
duced LITAF levels in RCCs without KKv1 expression
(KKv1 negative, approximating the KKv1 knock-down
situation) compared to RCCs expressing KKv1 (KKv1
positive) having increased LITAF expression (Additional
file 1: Figure S6B).
Table 2 Coding consequence of the read-through isoforms
Coding consequence n % Isoforms Functional consequence
1 = exon junction in-frame 6 11.8% Predicted fusion protein ORF
2 = exon junction outside of ORF 16 31.4% 5′partner fully conserved, 3′partner fully or partially
conserved OR regulatory OR NMD
3 = exon junction frameshift, premature stop codon 18 35.3% 5′partner partially conserved, 3′partner fully or partially
conserved OR regulatory OR NMD
4 = exon junction with non-coding RNA 10 19.6% Encoding partner partially conserved OR regulatory OR NMD
5 = antisense transcript 1 2.0% Regulatory
TOTAL 51
The numbering in column 1 is referring to the second to last column of Table 1. NMD, Nonsense-mediated decay; ORF, open reading frame.
Figure 2 Description of read-through BC039389-GATM. (A) DNA: Genomic structure of BC039389 and GATM on the DNA (−) strand. RNA: Two isoforms are
expressed from the genomic locus both utilizing the same alternative ATG in GATM exon 3 for putative protein translation. TaqMan assay positions and the
positions targeted by siRNAs are indicated. (B) Differential expression of BC039389-GATM isoform 1 (BGv1) in tumor vs. normal kidney tissue (**p < 0.01,
student’s t-test with Bonferroni correction). (C) Comparison of BGv1 and BGv2 expression in 14 frozen tumor/normal sample pairs using TaqMan assays.
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BC039389-GATM and KLK4-KRSP1 influence migration and
invasion inversely compared to their respective parent
transcript
We observed such inverse effects of read-through and
parent gene also on migratory and invasive properties of
cell lines (Figure 7 & Additional file 1: Figure S7).
ACHN had reduced migration/invasion, whereas Caki-2
had increased migration/invasion upon BGv1 knock-down
(Figure 7A). GATMwt knock-down had an opposing effect
on ACHN (increase) and Caki-2 (decrease). BG knock-
down with siBGv1 or siBGv2 alone or as double knock-
down in A704 was performed although this cell line is
minimally migratory and not invasive. All three BG
knock-downs caused increased migration, but siGATMwt
did not reverse this effect. BGv1 knock-down had no
gross influence on neither proliferation nor metabolic
rates in cancer cell lines (Additional file 1: Figure S8). A
small significant reduction in proliferation was seen
Figure 3 Description of read-through KLK4-KRSP1. (A) DNA: Genomic structure of KLK4 and KRSP1 on the DNA (−) strand. RNA: At least five
isoforms are expressed from the genomic locus. A pink line represents the splice site in KLK4 exon 2 which leads to a frameshift and subsequent
STOP codon in the RNA and the use of an alternative (alt) ATG START codon in putative KKv1 and KKv2 proteins. Green and brown lines indicate
the splice sites in KLK4 exon 5 (5 m = exon 5 middle, 5 m2 = exon 5 middle with different splice site) utilized in KKv2 and KKv3, respectively.
TaqMan assay positions and the positions targeted by siRNAs are indicated. (B) Expression levels of KLK4-KRSP1 isoform 1 (KKv1) in 46 frozen
tumor/normal sample pairs using TaqMan assay. (C) KKv2 expression in tumor/normal tissue pairs was screend for 46 KKv1-positive samples.
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Figure 4 Expression levels of the read-throughs’ parent genes in tissues. (A) Expression of the BC039389 and GATM parent genes alone
(wt, wild-type levels) or with read-throughs (tot, total levels) in 32 frozen tumor and matched normal samples. One sample had not suffient RNA
left for measuring wild-type and BC039389 tot levels. The location of the TaqMan assays is indicated in Figure 2A. (B) Expression of the KLK4 and
KRSP1 parent genes (wild-type and total transcript levels) in 13 samples expressing KKv1 read-through (left panel) or 19 samples not expressing
KKv1 (right panel). To be consistent in showing normal tissues, we artificially calculated KKv1 expression for 11 of 13 normal samples using the
cut-off of Ct40, as KKv1 was expressed only in 2 normal tissues of the KKv1-expressing cohort. The location of the TaqMan assays is indicated in
Figure 3A. Significance was calculated using student’s t-test in paired samples (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant).
Table 3 Correlations of KKv1 expression with clinical parameters
KKv1 expression Spearman’s rho
Yes No
n 46/169 (27%) 123/169 (73%)
age (y), median [range] 68 [32–86] 62 [22–86] ns
tumor size (cm), median [range] 6.3 [2.1-17.5] 5.0 [1.2-18] 0.204 **
subtype clear cell 25 102 0.274 **
papillary type 2 7 7
papillary type 1 2 13
chromophobe 12 0
Xp11 translocation 0 1
Fuhrman G1-2 19 88 0.208 **
grade G3-4 25 35
X 2 0
pT 1-2 27 86 ns
3-4 18 37
X 1 0
N yes 5 10 ns
no 27 70
X 14 43
M yes 11 29 ns
no 19 59
X 16 35
sex m 28 82 ns
f 18 41
VHL mutation yes 7 50 ns
no 3 15
unknown 36 58
**Correlation is significant at the 0.01 level (2-tailed) in univariate analysis.
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upon BGv1 knock-down in the normal kidney cell line
HK-2.
We observed alterations of migratory and invasive cap-
acities of cell lines under KKv1 knock-down. ACHN and
A704 had increased migration/invasion, whereas Caki-2
had reduced migration/invasion (Figure 7B). The knock-
down with siKLK4wt could reverse the effect of siKKv1 in
all three cell lines. None of the cancer cell lines altered
proliferative or metabolic rates under KKv1 depletion
(Additional file 1: Figure S8).
BC039389-GATM and KLK4-KRSP1 read-throughs likely
belong to the non-coding RNA class
Despite all our efforts, we were unable to identify endogen-
ous protein translated from BG or KK (see Additional file 1
and Additional file 1: Figures S9 and S10 for detailed ex-
perimentation). Although these experiments do not fully
eliminate the possibility that the read-throughs still pro-
duce functional proteins, it suggests that the effects which
we observed upon read-through knock-down are caused by
the RNA molecules themselves. We found KKv1 enriched
in the nuclear fraction of RCC cells (Additional file 1:
Figure S11A), possibly indicating a role in transcription
Figure 5 Survival analysis of KKv1-positive versus KKv1-negative ccRCCs.
Kaplan-Meier curves evaluating overall survival (OS) of a cohort of ccRCCs
with and without KKv1 expression.
Figure 6 Functional consequences of KLK4-KRSP1 and BC039389-GATM read-throughs on gene expression. (A, B) Heatmaps showing significantly
dysregulated genes by BGv1 (A) or KKv1 (B) from genome-wide expression analysis of cancer (Ca) cell lines Caki-2, ACHN, A704, LNCaP, sorted
from most down-regulated to most up-regulated in read-through knock-down vs. mock treatment. Pink rectangles mark the genes chosen for
TaqMan qPCR validation of the data sets (see also Additional file 1: Figures S4 and S5). Arrows indicate the genes chosen for further experimentation.
(C) IL8 expression in BG and GATMwt knock-down cells compared to si negative control (si nc). (D) IL8 levels measured by ELISA in BG and GATMwt
knock-down cells compared to si nc. (E) LITAF expression in KKv1 and KLK4wt knock-down cells. (F) LITAF levels on Western Blot in KKv1 and KLK4wt
knock-down cells compared to si nc. Significance was calculated using student’s t-test (*p < 0.05, ns = not significant).
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regulation. BGv1 was more abundantly expressed in the
cytosol (Additional file 1: Figure S11B), possibly suggesting
a role in processes taking place in this cellular compart-
ment. Further experiments are mandatory to pinpoint the
mechanism(s) by which the read-throughs are exerting
their function.
Discussion
This is the first study that aims at elucidating the role of
read-through RNA chimeras in RCC. We identified
read-throughs B039389-GATM and KLK4-KRSP1 up-
regulated in RCC compared to normal kidney. We show
that these read-throughs are able to functionally oppose
at least one of their two parent genes exemplified by al-
tering migration and invasion properties of cell lines and
by inversely regulating IL8 (BG) and LITAF (KKv1).
A direct comparison of our 324 read-through calls ob-
tained from RNA-Seq in RCC with six in breast cancer
[8] and 339 in prostate cancer [9] revealed only a mar-
ginal overlap of identical read-through calls. Such dis-
crepancies may be explained by diverging expression of
RNA read-throughs in different cancer types, but also by
the non-uniformity of the employed data filtering
strategies.
Only a few reports describe a putative functional im-
pact of read-throughs on cancer [4,8] with the most con-
vincing one reported for SLC45A3-ELK4 in prostate
cancer, where the read-through promotes cell prolifera-
tion but wild-type ELK4 does not [4]. Our study is the
first one in which functional consequences of read-
throughs were investigated in RCC.
The function of BC039389, one of the parent genes of
BG, is yet unknown. The second parent gene GATM cata-
lyzes the rate limiting step of creatine synthesis and its ex-
pression is seen in various tissues, with the highest levels
observed in kidney. It was shown that both the protein
(Additional file 1: Figure S9C and [18]) and the mRNA
(Oncomine database) expression of GATM is reduced in
RCC compared to normal kidney. We hypothesize that
after transcription of GATM, the 3′ exons (i.e. exon 7,
GATMtot) are more susceptible to degradation compared
to the 5′ exons (i.e. exon 1, GATMwt). This may explain
both the reduction of GATMtot in RCC and the un-
changed expression of GATMwt when compared to nor-
mal kidney, seen in our study. Steady transcription of
exon 1 is probably required to be spliced for the sake of
generating BG. Even under the condition of reduced
GATM in tumor, there still exists a manifold excess of
GATM mRNA over BG read through, preventing us from
detecting the increase of BG when measuring GATMtot in
tumor. We suspect that BG expression is not only driven
by BC039389 increase, but that also GATM loss plays a
role since such loss evokes an increase of BG expression,
as reflected by the significant induction of BGv1 by 1.5- to
2-fold in the experiment with siGATMwt knock-down in
ACHN and Caki-2 (Additional file 1: Figure S7A). We
used microarrays to find out whether BGv1 influences the
expression of genes. The most prominent target gene was
IL8, a cytokine. IL8 regulation is critical in a lung metasta-
sis mouse model where it was shown that RCC cells with
high IL8 have less competence to metastasize because
they seem to attract tumor-cytotoxic neutrophils to the
metastatic niche in the lung [19]. Preventing the recruit-
ment of such killer neutrophils through downregulation of
IL8 may well be one of the synergistic functions of redu-
cing GATM and increasing BG in cancer cells. Hence, we
suspect a rather tumor-promotive function of BG. We can
observe this in form of reduced migration/invasion of
ACHN cells upon BGv1 knock-down, but this effect is cell
line-dependent. Regarding the effects on IL8 and migration/
Figure 7 Functional consequences of KLK4-KRSP1 and BC039389-GATM read-throughs on migration and invasion. (A, B) Invasion and migration changes in
cell lines under read-through or parent gene knock-down in comparison to si negative control (si nc) (*p < 0.05 by student’s t-test). The migration/invasion of
cells was measured in real-time and first plotted as delta cell index (no. of migrated cells) per given time period (see Additional file 1: Figure S7). Then the
slopes of the curves of cells treated with targeting siRNAs were calculated in comparison to the baseline si nc curve and plotted as bar chart, where a minus
slope indicates less migration, and a positive slope more migration than si nc, respectively. These experiments were performed as technical duplicates in
biological replicates as indicated.
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invasion as two independent examples of reciprocal regula-
tion, we can corroborate the theory that the read-through
transcript BG and wild-type GATM are functionally oppos-
ing each other in such a manner that ultimately the result
may be beneficial for tumorigenesis.
Recently, the KLK4-KRSP1 read-through has been de-
scribed in a publication on pseudogenes [20]. The authors
describe high expression of, what we named, KKv1 in
prostate cancer. Both parent genes of this read-through are
part of the large family of tissue kallikreins. With the emer-
ging role of tissue kallikreins in cancer [21], KLK4 expres-
sion has been profiled in several cancer tissues e.g. prostate
[22], ovary [23], endometrium [24] and colon [25]. Elevated
KLK4 levels were frequently associated with higher tumor
grade in endometrial and prostate cancer [24,26] and poor
prognosis in ovarian cancer [23]. Kallikreins are secreted
proteases and KLK4 appears to be the only representative
of this family with pro-proliferative function mainly local-
ized to the nucleus [22]. Little is known about the function
of KRSP1. It potentially can be translated into a protein
which is primarly present in the nucleus [27]. Also for KK,
we hypothesize that the 5′ parent’s expression is driving the
read-through’s expression, as KLK4tot and KLK4wt levels
are higher in tumors expressing KKv1 than in their
matched normal kidney tissues. Similar to our hypothesis
of an interplay between GATM loss and BG increase, the
parent genes’ expression data for KK is hinting towards a
role of KRSP1 loss in KK expression. We were unable to
directly proof such a link, since we could not design a
siRNA targeting specifically KRSP1wt (as pseudogene,
KRSP1 (exons 1–3) has great homology to all members of
the family of tissue kallikreins) to perform a KRSP1wt
knock-down eventually increasing KKv1 expression. After
microarray analysis, we found LITAF as a major target gene
of KKv1. The literature about LITAF function in cancer is
inconsistent. One report mechanistically proofs LITAF as
p53-repressed [28]. Putting this in the context of RCC,
where loss of pVHL in 70% of ccRCCs may contribute to
destabilization of p53 [29], one could expect increased
LITAF in these ccRCCs. With KKv1, we have found yet
another player in LITAF up-regulation expressed in 20%
of ccRCCs. We also report KKv1 expression frequently as-
sociated with pRCC type 2 and chrRCC, histological RCC
subtypes in which VHL and p53 are largely functional.
There, LITAF up-regulation could be mediated almost ex-
clusively by KKv1. Since we observe worse survival for pa-
tients in the presence of KKv1, we would attribute KKv1
rather tumor-promotive properties. However, a tumor-
promotive effect of KKv1 on migration/invasion of RCC
cells is cell line-dependent and may be one reason why
KKv1 did not correlate with local or distant metastasis in
patients.
Although previous reports suggest that some read-
throughs encode fusion proteins [5,8,16,17], we and others
[7] suspect that most read-throughs suit the class of non-
coding RNA. In accordance with Prakash et al. [7], most
of the read-throughs we are reporting here are not pre-
dicted to encode fusion proteins. Any analysis of endogen-
ous protein levels is difficult in consideration of the low
levels of read-through expression. Low RESPER scores
and high Ct values (Ct 27–40 compared to Ct 18 for the
reference gene PPIA) demonstrate that read-throughs are
mostly transcribed at rather low rate. And despite all our
efforts, we have found no proof of protein expression from
either BG or KKv1.
In summary, we demonstrate for the first time that read-
throughs act as regulators by counteracting their parent
genes in suppressing or activating genes or mechanisms in
renal cancer. Yet, how they regulate and how they them-
selves are regulated is still to be determined. Most of our
read-throughs were similarly expressed in tumor and nor-
mal tissue. However, the fact that BC039389-GATM and
KLK4-KRSP1 are two examples of read-throughs expressed
at higher levels in tumor tissue hints towards a rather onco-
genic function for some read-throughs. This coincides with
the hypothesis that RNA chimerism is more frequently ob-
served in prostate cancer than in benign prostate tissue [11].
Conclusions
A growing body of literature on RNA chimeras indicates
that chimeric read-through transcripts have implications
in cancer. We show that such read-through transcripts are
abundantly expressed in renal cell carcinoma and, on the
basis of two examples BC039389-GATM and KLK4-
KRSP1, may be tumor-promoting and impacting cellular
properties in a way which inverses the effect of their wild-
type parent transcripts.
Methods
RNA extraction
RNA extractions from fresh frozen RCC tissues, matched
adjacent normal kidney tissue and cell lines were per-
formed with RNeasy kit (Qiagen). Prior to ethanol precipi-
tation the frozen tissues were cut to 10 μm thick sections
and homogenized in RTL buffer + β-Mercapthoethanol
for 2 min at 30Hz (twice) in a TissueLyser (Qiagen). Cell
lines were homogenized using QIAshredder columns
(Qiagen). Our retrospective study fulfilled the legal condi-
tions according to Article 34 of the Swiss Law “Human-
forschungsgesetz (HFG)”, which, in exceptional cases,
allows the use of biomaterial and patient data for research
purposes without informed consent, if i) it is impossible
or disproportionately difficult to obtain patient consent; ii)
there is no documented refusal; iii) research interests pre-
vail the individual interest of a patient. Law abidance of
this study was reviewed and approved by the ethics com-
mission of the Canton Zurich (KEK-ZH-Nr. 2011-0072/4).
Pflueger et al. BMC Genomics  (2015) 16:247 Page 11 of 14
Whole transcriptome sequencing and computational
read-through analysis
Seven fresh frozen cancer tissues were subjected to paired-
end (PE) whole transcriptome sequencing on Illumina GAII
followed by nomination of chimeric transcripts by the ana-
lysis software FusionSeq as previously described [30]. Only
read-through candidates, characterized by PE reads cover-
ing two neighboring genes on the same DNA strand, were
considered for this study. Inter-, intra- and cis chromo-
somal candidates were disregarded.
Candidate validation by RT-PCR and quantitative
PCR (qPCR)
Frozen RCC and normal kidney tissue was used for candi-
date validation. The putative RNA junction region of se-
lected read-throughs, narrowed down by FusionSeq, was
amplified by at least two different primer combinations
(Additional file 2: Table S1). Resulting amplicons were sepa-
rated on agarose gels, extracted and Sanger sequenced to
proof their identity (Additional file 1: Figure S2). Quantita-
tive TaqMan assay design was based on the results gained
from Sanger sequencing and allowed reliable detection
mostly for the prominent isoform(s) of a given read-
through event as indicated in Table 1. Primers and probes
were purchased from Microsynth AG (Balgach, CH). Taq-
Man qPCRs were performed on Real-Time PCR Systems
from Applied Biosystems using the TaqMan RNA-to-Ct 1-
step kit (Life technologies) in the presence of 0.2 μM of
each primer and 0.9 μM of the probe. Differential expres-
sion of all genes was calculated relative to the endogenous
control PPIA.
Cell culture
Cell lines were purchased from ATCC (Molsheim Cedex, F)
and cultivated accordingly. The benign kidney cell line HK-2
was propagated in medium K-1 which was originally de-
scribed [31] and consists of a 1:1 mixture of DMEM and
Ham’s F-12 Nutrient mixture supplemented with a mixture
of hormones (2.5 μg/ml insulin, 0.625 ng/ml prostaglandin
E1, 16.9 pg/ml (or 26 pM) 3,3,5 Triiodothyronine T3, 2.5
μg/ml transferrin, 9 ng/ml (or 25 nM) hydrocortisone).
Additionally, we supplemented with 5% FCS, 1% penicillin/
streptomycin, 25 mM HEPES, 5 ng/ml EGF and 0.865
ng/ml (or 50pM) sodium selenite. All cell lines were au-
thenticated (Microsynth).
siRNA treatment
Read-through specific knock-down was achieved by placing
the siRNA into the exon junction of KKv1 and BGv1 with
at least 8 nucleotides covering each parent gene. Read-
through specific-, Lamin A/C (LMNA, pos. ctrl.) and non-
targeting (si nt = si non-targeting) siRNAs were purchased
from Microsynth AG. For sequences see Additional file 3:
Table S2. AllStars Negative Control siRNA (si nc) was
purchased from Qiagen. Cell line-specific knock down
protocols were established using siRNA concentrations of
24nM, 48nM, 72nM, 120nM and 240nM. Chosen was the
concentration where LMNA pos. ctrl. was efficiently
knocked-down (>50%) and nt siRNAs had no effect. Time
points for testing knock-down effect were 24 h, 48 h, 72 h
and 96 h. Chosen was the time point when read-through
specific siRNAs had sufficient knock-down (>70%) but
wild-type parent genes were unaffected (see Additional file
1: Figures S4, S5, S7 and S8). Optimal transfection re-
agents for each cell line were titrated using pos. ctrl.
siRNA: Caki-2, ACHN, LNCaP and HK-2 were pre-
seeded over-night before transfection with HiPerFect
(Qiagen), A704 was pre-seeded over-night before transfec-
tion with Lipofectamine RNAiMAX (Life technologies)
and HEK293 were transfected using a fast-forward proto-
col with Lipofectamine 2000. Both lipofectamine agents
required a medium change after 6 h (A704) or 10 h
(HEK293).
Microarray gene expression analysis of read-through-
specific knock-down cell lines
For genome-wide expression analysis, only RNA samples
with >85% KKv1 or BG knock-down were used (Additional
file 1: Figures S4A and S5A). RNA quality control, sample
preparation, chip run (human Affymetrix Gene 1.1 STArray
strips) and data pre-processing were performed by the Func-
tional Genomics Center Zurich (FGCZ). Data analysis was
done using B-Fabric, an open software provided by the
FGCZ. Only genes with a log2 ratio ≥ (±)0.5 and an uncor-
rected p-value ≤0.05 between mock (transfection reagent)
and siRNA treated cell lines were considered. Heatmaps
were constructed using the MultiExperiment Viewer (MeV).
Regulation of selected target genes, relative to PPIA, was
evaluated by TaqMan qPCR (Additional file 1: Figures S4D
and S5D).
ELISA
To measure IL8 protein levels by ELISA, siRNA knock-
downs were performed in cell lines Caki-2 (60 000 cells/
well of a 12-well plate) and ACHN (150 000 cells/well of a
12-well plate) for 48 h, and A704 (125 000 cells/well of a
12-well plate) for 72 h. Cells were harvested by trypsiniza-
tion, the pellet was washed with PBS and the whole cell
lysate was extracted using 30ul of RIPA buffer. Protein
concentration was measured by Pierce BCA Protein Assay
Kit (Thermo Scientific). Twice 10ul of the whole cell lys-
ate was used in the ELISA assay (Human IL8 ELISA
Ready-SET-Go! (2nd Generation) (eBioscience Affymetrix,
Austria)). The subtracted absorbance of the samples’
duplicates was compared to the standard curve using the
4-parameter logistic curve fit in GraphPad Prism. The
resulting mean IL8 concentrations of the samples were nor-
malized to the protein content in the whole cell lysate.
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Then, the fold change between the respective si nc samples
and knock-downs of the read-throughs or wild-type genes
was calculated and plotted as mean + SEM for technical
quadruplicates.
Migration/invasion assays
Migratory/invasive potential of RCC cell lines was measured
in real-time using the xCELLigence RTCA DP System
(ACEA Biosciences, San Diego). This technique adapts the
boyden chamber principle and combines it with impedance
measurements. Cells seeded in the upper chamber of a mi-
croplate containing “low chemoattractant (1% FCS)” can mi-
grate through the microporous membrane into the lower
chamber being the “high chemoattractant (10% FCS)” com-
partement. Migrated cells adhere to the gold micro-
electrode sensor located at the lower side of the membrane
and lead to an increase in impedance, which is measured by
the RTCA DP instrument. Knock-down of read-throughs,
wild-type parent genes and negative control siRNA were
performed for 48 h (BG: ACHN,Caki-2; KK: A704) and 72 h
(BG: A704; KK: ACHN, Caki-2) (Additional file 1: Figure
S7A) before seeding the cells into the microplates in dupli-
cates. Optimal cell seeding densities were determined in
pre-experiments. Impedance measurements were performed
for 72 h (Additional file 1: Figure S7B-C). For invasion as-
says, the membrane was coated with Matrigel Basement
Membrane Matrix (BD Biosciences, 400ug/ml protein in 1%
FCS-containing medium).
Availability of supporting data
The junction sequences of the read-throughs are deposited
to Genbank under accession number [GenBank:KM576708-
KM576757].
Additional files
Additional file 1: Describes in detail (i) the results of the
experiments performed to substantiate or negate protein
translation from the read-throughs, (ii) additional Material and
Methods omitted from the main manuscript because they were
used in experiments featured only in additional figures and (iii)
additional figures 1–11 with figure legends.
Additional file 2: Table S1. Lists the primer and probe sequences.
Additional file 3: Table S2. Lists the siRNA sequences.
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